Q8NEB9 (PK3C3_HUMAN) Homo sapiens (Human)
Phosphatidylinositol 3-kinase catalytic subunit type 3 UniProtKBInterProSTRINGInteractive Modelling
887 aa; Sequence (Fasta) ;
4 identical sequences: Pan troglodytes: A0A2I3SV31, A0A6D2WQM8; Pan paniscus: A0A2R9AAE5; Gorilla gorilla gorilla: A0A2I2ZRM9
It is possible new templates exist for this target since these models were created.
Available Structures
22 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| human complex II-BATS bound to membrane-attached Rab5a-GTP |
Heteromer P20339; Q14457; Q99570; Q9P2Y5; | 1×GTP; 1×MG; | ||||
| Assess | ||||||
| Structure of human ULK1C:PI3KC3-C1 supercomplex |
Heteromer O75143; O75385; Q14457; Q6ZNE5; Q8TDY2; Q99570; | |||||
| Assess | ||||||
| Structure of human PI3KC3-C1 complex |
Heteromer Q14457; Q6ZNE5; Q99570; | 1×ADP; | ||||
| Assess | ||||||
| Structure of VPS34 LIR motif bound to GABARAP | homo-3-mer | 6×SO4; 6×EDO; 6×GOL; | ||||
| Assess | ||||||
| Structure of VPS34 LIR motif (S249E) bound to GABARAP | homo-3-mer | 3×PGE; | ||||
| Assess | ||||||
| Structure-based exploration of selectivity for ATM inhibitors in Huntingtons disease | monomer | 1×OZ8; | ||||
| Assess | ||||||
| Optimization of potent and selective ATM inhibitors suitable for a proof-of-concept study in Huntin… | monomer | 1×H2E; | ||||
| Assess | ||||||
| Crystal structure of VPS34 in complex with inhibitor SB02024 | monomer | 1×A1H4E; 2×PEG; 1×IMD; 3×DMS; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of human PIK3C3 in complex with 3-[4-(4-Morpholinyl)thieno[3,2-d]pyrimidin-2-yl]-… | monomer | 1×AJZ; 2×CL; 1×GOL; | ||||
| Assess | ||||||
| Human PIK3C3 crystal structure | monomer | |||||
| Assess | ||||||
| Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4… | monomer | 2×NA; 1×JXM; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF VPS34 IN COMPLEX WITH SAR405. | monomer | 4×SO4; 1×1TT; | ||||
| Assess | ||||||
| Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4… | monomer | 1×EUT; | ||||
| Assess | ||||||
| Structure of the VPS34 kinase domain with compound 14 | monomer | 3×NA; 1×7IH; 1×EDO; 2×GOL; | ||||
| Assess | ||||||
| Structure of the VPS34 kinase domain with compound 14 | monomer | 1×GOL; 1×7IK; | ||||
| Assess | ||||||
| Structure of the VPS34 kinase domain with compound 5 | monomer | 1×7IQ; 2×GOL; 4×NA; | ||||
| Assess | ||||||
| Crystal structure of VPS34 in complex with (2S)-8-((3R)-3- Methylmorpholin-4-yl)-1-(3-methyl-2-oxo-… | monomer | 1×RBQ; | ||||
| Assess | ||||||
| Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4… | monomer | 3×SO4; 1×RBQ; | ||||
| Assess | ||||||
| Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4… | monomer | 2×SO4; 1×7A5; | ||||
| Assess | ||||||
| Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4… | monomer | 1×SO4; 1×GOL; 1×UJB; | ||||
| Assess | ||||||
| The crystal structure of Human VPS34 in complex with a selective and potent inhibitor | monomer | 1×5QS; 1×NA; | ||||
| Assess | ||||||
| The crystal structure of Human VPS34 in complex with PIK-III | monomer | 1×GOL; 1×2UG; | ||||
| Assess | ||||||
4 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7bl1.1.B | monomer | 0.66 | 100.00 | |||
| Assess | ||||||
| 6gvg.1.A | monomer | 0.56 | 27.39 | |||
| Assess | ||||||
| 6g6w.1.A | monomer | 0.54 | 28.83 | |||
| Assess | ||||||
| 1e7u.1.A | monomer | 0.52 | 28.94 | |||
| Assess | ||||||